There are currently 434 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845
Recruiting
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +19 locations
Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Register for Updates
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Beverly Hills Cancer Center, Beverly Hills, California +21 locations
Conditions: Non Small Cell Lung Cancer, Lung Cancer, Breast Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT04824027
Recruiting
For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Columbia University Irving Medical Center/NYP, New York, New York
Conditions: Breast Cancer
Register for Updates
VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients
NCT06878547
Recruiting
Purpose: This study will evaluate how measurements of tissue stiffness, viscosity, and anisotropy using non-invasive ultrasound imaging correlate with breast tumor malignancy and response to chemotherapy. Participants: Up to 200 women with benign or malignant breast tumors for arm 1 and up to 50 women undergoing neoadjuvant chemotherapy in the breast for arm 2 will be recruited. Procedures (methods): The research team will use an ultrasound scanner to acquire non-invasive elastography data fro... Read More
Gender:
FEMALE
Ages:
Between 20 years and 90 years
Trial Updated:
05/27/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Breast Cancer
Register for Updates
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599
Recruiting
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Research Site, Gilbert, Arizona +14 locations
Conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer
Register for Updates
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients
NCT05585788
Recruiting
This research study will evaluate the use of, and participants experience with, a new device called Addinex that safely stores and dispenses opioid medication. The purpose of this study is to evaluate the use of the Addinex device in cancer patients undergoing cancer-related surgery that require pain control with opioids after the surgery. Participants will be asked to answer questions about their medical history and background, fill out questionnaires, use a mobile application associated with t... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/27/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Opioid Use, Breast Cancer
Register for Updates
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT04614194
Recruiting
The purpose of this study is to better understand how the immune system plays a role in fighting breast cancer and specifically research if the immune system response against breast cancer can be improved with endocrine therapy and cyclin dependent kinase inhibitor therapy in patients with hormone receptor positive breast cancer. This will be studied by collecting tumor tissue and blood samples before and after 2 weeks of study treatment with commonly used endocrine therapy and cyclin dependent... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Parkland Hospital, Dallas, Texas +1 locations
Conditions: Breast Cancer
Register for Updates
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT02830724
Recruiting
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70. Objectives: To see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe. Eligibility: Adults age 18... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
05/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer
Register for Updates
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139
Recruiting
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Angeles Clinic and Research Institute, Los Angeles, California +32 locations
Conditions: Breast Cancer, Solid Tumors, Adult
Register for Updates
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
NCT06954337
Recruiting
Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do this through a new option called enhanced telehealth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Prostate Cancer
Register for Updates
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Clinical Trial Site, Tucson, Arizona +173 locations
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Register for Updates
Multi-center MRD Registry for Inflammatory Breast Cancer
NCT06966050
Recruiting
To collect data from participants with IBC who may have had MRD testing and may have surgery in the future.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates